BeiGene, a global biotechnology company focused on developing and commercialising innovative medicines worldwide, has announced the first step in its expansion in the MENA region with the formal opening of its office in Dubai, United Arab Emirates.
Founded in 2010, BeiGene has built one of the largest and most efficient oncology research teams in the world, with a portfolio of 17 approved assets (three internally developed) and a broad and deep pipeline focused on haematology and solid tumours with the potential to address 80 per cent of the world’s cancers by incidence.
The new office is located within Dubai Science Park and will house BeiGene’s administrative, commercial, and medical colleagues.
“Our expansion into the Middle East and North Africa region is a significant step in our company’s ongoing global expansion and an opportunity to reinforce BeiGene’s commitment to deliver innovative, affordable and accessible medicines to more patients around the world,” said Jurij Petrin, Head of New Market Development at BeiGene.
“Dubai, renowned as the center of regional and international trade in the United Arab Emirates, is the ideal location for our first office in the region, signalling our growing presence in MENA and enabling us to better serve patients in the area.”
“We’re thrilled to announce our expansion into the United Arab Emirates, a pivotal location in the worldwide fight against cancer. This move marks our commitment to MENA, and we’re eager to grow our talented team as we introduce innovative medicines to the region,” commented Mohammed Al-Kapany, General Manager, MENA.
“Our presence at Dubai Science Park, with its state-of-the-art facilities, will best support our team and collaborations within the dynamic regional landscape to ensure patients across the region are able to equally access our innovative therapies.”
Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, part of TECOM Group, said: “Cancer remains one of the leading causes of death worldwide, affecting millions of people and their families every year. Greater collaboration in the healthcare and biotechnology sector is essential to deliver breakthrough innovations that can improve survival rates and long-term outcomes for patients.
“Dubai Science Park is committed to making a meaningful impact in cancer treatment and nurturing innovative partnerships within the healthcare and biotechnology communities to benefit patients around the world. We are aligned with the goals of Dubai Economic Agenda ‘D33’, Dubai Research & Development Programme, and ‘We the UAE 2031’ vision to localise scientific advancements that deliver global impact, and welcome BeiGene’s collaboration in our endeavour to deliver healthcare advancements across the world.”
BeiGene will host a ceremony today to celebrate the formal opening of the office, welcoming various stakeholders from across the government, healthcare and business sectors, as well as the patient community.